This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019 Sep 1;40(33):2782-2784.

doi: 10.1093/eurheartj/ehz087.

Lipoprotein (a), arterial inflammation, and PCSK9 inhibition

Jean-Claude Tardif¹, Eric Rhéaume¹, David Rhainds¹, Marie-Pierre Dubé¹

Affiliations

PMID: 30838412
DOI: 10.1093/eurheartj/ehz087

Editorial

Lipoprotein (a), arterial inflammation, and PCSK9 inhibition

Jean-Claude Tardif et al. Eur Heart J. 2019.

. 2019 Sep 1;40(33):2782-2784.

doi: 10.1093/eurheartj/ehz087.

Authors

Jean-Claude Tardif¹, Eric Rhéaume¹, David Rhainds¹, Marie-Pierre Dubé¹

Affiliation

¹ Research Centre, Montreal Heart Institute, Université de Montréal, Montreal, Canada.

PMID: 30838412
DOI: 10.1093/eurheartj/ehz087

No abstract available

PubMed Disclaimer

Comment on

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, Sabatine MS, Mani V, Fayad ZA. Stiekema LCA, et al. Eur Heart J. 2019 Sep 1;40(33):2775-2781. doi: 10.1093/eurheartj/ehy862. Eur Heart J. 2019. PMID: 30561610 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Miscellaneous
- NCI CPTAC Assay Portal